Time for Camras Awards


The Association for Research in Vision and Ophthalmology Foundation for Eye Research is accepting nominations for the 2013 AFER/Pfizer Ophthalmics/Carl Camras Translational Research Awards.

Key Points

The Camras Awards honor up to three young investigators for their contributions to translational research in ophthalmology and carry $10,000 honoraria. Nominations are open to all members of the vision research community who meet the following criteria:

All nominations must be submitted online by March 1, 2012. The awards will be presented at the 2013 ARVO annual meeting keynote session in Seattle. Go to http://www.arvofoundation.org/ for more information.

ARVO education courses-full- and half-day courses-will take place the day before the annual meeting opens, Saturday, May 5. Interested participants must register for these courses separate from-and in advance of-the annual meeting registration.

Full-day courses include:

Half-day topics include:

CME reminder

Continuing medical education (CME) credits are offered for CME-eligible annual meeting sessions. ARVO is accredited by the Accreditation Council for Continuing Medical Education to provide CME for physicians.

Typically, the maximum number of credits that can be claimed for attending ARVO annual meeting activities has been in the range of 27 to 30 AMA PRA Category 1 Credits. Physicians that are not licensed in the United States who participate in this CME activity are eligible for AMA PRA Category 1 Credits.

Endpoints summary published

The vision research community and the FDA are discussing how to adopt and/or implement safe and effective endpoint measures for assessing glaucoma therapies in U.S. clinical trials.

Clinicians, researchers, policymakers, and representatives from industry and vision associations participated in a 1-day symposium sponsored by the National Institutes of Health's National Eye Institute (NEI) and the FDA September 2010.

The meeting is summarized in an article, "Glaucoma Research Community and FDA Look to the Future, II: NEI/FDA Glaucoma Clinical Trial Design and Endpoints Symposium:

Measures of Structural Change and Visual Function," published in the October 2011 issue of Investigative Ophthalmology &Vision Science. Go to http://www.IOVS.org/ for more information.

Author InfoJoanne Olson is director of communications, marketing and sales, for the Association for Research in Vision and Ophthalmology. Readers may contact her at 240/221-2923 or jolson@arvo.org

© 2024 MJH Life Sciences

All rights reserved.